Published in Gene Therapy Weekly, October 21st, 2004
According to a recent review published in the journal Molecular Cancer Therapeutics, "The importance of the prostaglandin (PG) synthesis pathway, particularly the rate-limiting enzymatic step catalyzed by cyclooxygenase, to colorectal carcinogenesis and development of novel anticolorectal cancer therapy is well established."
"The predominant PG species in benign and malignant colorectal tumors is PGE2 . PGE2 acts via four EP receptors termed EP1 to EP4. Recently," wrote M.A. Hull and colleagues, "EP receptors have been...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.